A new study by the British Regulatory Agency for Medicines and Medical Products (MHRA) and Genomics England is ready to explore whether genetic differences affect the risk of acute pancreatitis after the use of GLP-1 receptor agonists is OzemEmpic, Mounjaro and Wegovy-Pro type 2.
According to Sky News, the British Regulatory Agency for Medicines and Medical Products (MHRA) received 181 reports on acute or chronic pancreatitis associated with Mounjaro weight loss, including five deaths.
The GLP-1 Wegovy and Ozmpic drugs were associated with 113 reports on pancreatitis and one death, the outlet said.
Sky News also noted that other, less commonly used GLP-1 drugs were similarly associated with cases of pancreatitis and additional deaths.
Genetic binding to side effects
The yellow card, the first of its kind, will collect genetic data from patients who have been hospitalized with acute pancreatitis suspect that they are associated with GLP-1 drugs. These drugs, often called “thin punches”, mimic natural hormones that regulate appetite and sugar in the blood. Although rare, acute pancreatitis is a serious condition that has been reported to users.
“This is a prevention of side effects before they happen,” Dr. Alison Cave, main security director MHRA. “Almost a third of side effects could be prevented by genetic testing. This study is the main step to personalized medicine.”
How does it work
Patients hospitalized with acute pancreatitis, while on GLP-1 medicines, they are asked to report their experience through a yellow card scheme. Healthcare workers are also asked to report suspicious cases and refer to patients.
After presenting a yellow card, the MHRA will contact the Eligible Biobank Study. Participants will be asked to provide saliva sample sent by mail to help identify genetic factors that can increase the risk of pancreatitis. The sample will be used by approved scientists to understand whether the side effects are associated with specific genetic features.
What do you need to know about GLP-1 medicinal products (“Skinny Jabs”)
What are: GLP-1 receptor agonists (GLP-1), such as OZEM, Wegovy, Mounjaro and Rybelsus, help regulate appetite and blood sugar by imitating natural hormone. Some like Mounjaro also affect the other hormone.
In the UK, GLP-1 are licensed only for people with obesity or diabetes 2. The use of their weight loss is not approved.
These drugs must be prescribed by a healthcare professional after a proper consultation. Are available via NHS (in selected cases) or privately through legitimate clinics.
Never buy unregulated sources such as beauty salons or social media. False or unauthorized GLP-1 products can cause serious side effects. Trust only pharmacies with regulations.
(Tagstotranslate) Risks for weight loss weight loss
